JG
NBIX icon

Jefferies Group’s Neurocrine Biosciences NBIX Stock Holding History

Jefferies Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-29,900
Closed -$2.87M – 1882
2021
Q3 		$2.87M Buy
29,900
+26,200
+708% +$2.47M 0.02% 623
2021
Q2 		$360K Sell
3,700
-21,800
-85% -$2.09M ﹤0.01% 1260
2021
Q1 		$2.48M Sell
25,500
-30,000
-54% -$3.15M 0.02% 603
2020
Q4 		$5.32M Buy
55,500
+48,000
+640% +$4.64M 0.04% 385
2020
Q3 		$721K Sell
7,500
-32,800
-81% -$3.79M 0.01% 898
2020
Q2 		$4.92K Buy
40,300
+7,500
+23% +$829K 0.06% 279
2020
Q1 		$2.84M Buy
+32,800
New +$3.21M 0.03% 513
2019
Q2 		– Sell
-65,000
Closed -$5.73M – 2754
2019
Q1 		$5.73M Sell
65,000
-52,200
-45% -$4.36M 0.05% 385
2018
Q4 		$8.37M Buy
117,200
+92,200
+369% +$8.83M 0.07% 233
2018
Q3 		$3.07M Sell
25,000
-80,500
-76% -$9.13M 0.02% 778
2018
Q2 		$10.4M Buy
105,500
+18,000
+21% +$1.61M 0.06% 255
2018
Q1 		$7.26M Buy
+87,500
New +$7.39M 0.04% 344
2016
Q1 		– Sell
-15,000
Closed -$849K – 2456
2015
Q4 		$849K Buy
+15,000
New +$762K ﹤0.01% 1245
2013
Q4 		– Sell
-411,200
Closed -$4.66M – 2128
2013
Q3 		$4.66M Buy
411,200
+363,800
+768% +$5M 0.05% 346
2013
Q2 		$634K Buy
+47,400
New +$582K 0.01% 971

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jefferies Group's NBIX Position: Q1 2022 in Review

Jefferies Group sold out of Neurocrine Biosciences (NBIX) in Q1 2022, closing a stake of 19,865 shares — an estimated $1.69M sold.

Jefferies Group first reported a position in NBIX in Q2 2013 and held it in 24 quarters. The position peaked at $13M in Q3 2019. 426 funds tracked by Wall St. Rank hold NBIX as of Q1 2022.

  • Jefferies Group reported no remaining Neurocrine Biosciences position as of Q1 2022 after selling out during the quarter.
  • Jefferies Group sold 19,865 Neurocrine Biosciences shares in Q1 2022, an estimated $1.69M.
  • Jefferies Group first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 24 quarters.
  • Jefferies Group's Neurocrine Biosciences position peaked at $13M in Q3 2019.
  • 426 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.